# Recurrent Glioblastoma (rGBM)

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/recurrent-glioblastoma-rgbm
Canonical HTML page: https://getbiobrief.com/entity/recurrent-glioblastoma-rgbm

## Timeline

- **2026-06-15**: Press Release Issued — Rznomics announces the presentation and key findings via PRNewswire, making the data public to investors and the biomedical community.
- **2026-06-13**: Interim Data Presentation at ASNO 2026 — Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim Phase 1/2a results of RZ-001 in recurrent glioblastoma, reporting safety and early efficacy signals.

## Recent coverage (1 stories)

### Rznomics' RZ-001 Achieves 0% DLT Rate in Phase 1/2a rGBM Trial, Validating RNA Ribozyme Platform
2026-07-27 03:00:55 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Rznomics' Phase 1/2a data for RZ-001, an RNA trans-splicing ribozyme gene therapy, shows zero dose-limiting toxicities and promising efficacy in recurrent glioblastoma, marking a key milestone for the platform.
Full story: https://getbiobrief.com/story/rznomics-rz001-zero-dlt-rgbm-trial

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.